OBJECTIVES: To assess the relationship between hormone replacement therapy (HRT) and coronary artery calcium (CAC). DESIGN: Cross-sectional. SETTING: Established population-based cohort in Reykjavik, Iceland. PARTICIPANTS: Women (mean age 76 AE 5) who had completed questionnaires on HRT use (N = 2,867). MEASUREMENTS: Coronary artery calcium assessed using computed tomography was the outcome variable and was compared between women with history of HRT and those who had never used HRT and analyzed according to age, length of use, and time after menopause that HRT was initiated. RESULTS: Eight hundred seventy-two (30.4%) participants had used HRT, and 312 (10.9%) were current users. After adjustment for age, other late-life variables, and a propensity score based on midlife data for HRT use as observed in late life, there were significant negative associations between CAC and history and length of HRT use. This association was evident in all age categories. When HRT had been used for longer than 15 years, median CAC level was less than 50% of that observed in never users. The lowest CAC was observed in those who started HRT within 5 years after menopause. The prevalence of coronary events was comparable in both groups. CONCLUSION: A strong association was found between long-term HRT use and low CAC. The negative association between duration of HRT and CAC was evident in all age groups of older women. J Am Geriatr Soc 65: 200-206, 2017. 
T he later onset of cardiac events in women than in men has been linked to a protective effect of estrogens. 1 Results regarding the effect of postmenopausal hormone replacement therapy (HRT) and cardiovascular mortality that have emerged from several clinical trials have conflicted with results of observational studies, with clinical trials failing to find cardiovascular benefits of HRT that had been found in observational studies in postmenopausal women. [2] [3] [4] [5] Although the initial findings from the Women's Health Initiative (WHI) indicated substantial cardiovascular risks from use of HRT in postmenopausal women, an analysis of the estrogen-only arm within the WHI suggested a potential lower risk of coronary heart disease if estrogen replacement therapy was initiated within 10 years after menopause. [5] [6] [7] Another recently published randomized clinical trial of HRT for prevention of osteoporosis suggests that initiation of HRT early after menopause significantly reduces the composite endpoint of heart failure, myocardial infarction, and mortality. 8 Coronary artery calcium (CAC) is an established marker of subclinical atherosclerosis, and it has been shown that assessment of CAC can improve risk predictions for coronary events after adjustment for traditional risk factors. 9, 10 In a substudy of the WHI, CAC of women aged 50-59 at randomization was assessed after trial completion. The women randomized to the conjugated estrogenonly arm had significantly lower CAC than those in the placebo arm after a mean of 7.4 years of treatment. 11 In contrast, the Kronos Early Estrogen Prevention Study did not show an effect of up to 4 years of HRT (initiated within 3 years after last menses) on the progression of CAC. 12 Cardiovascular disease is a major cause of death in women aged 65 and older. 13 During the 10 years since the publication of the first WHI report, a substantial decrease in the use of HRT has been observed worldwide. 14 The early discontinuation of the WHI limits the possibility of answering the question of whether long-term therapy will reduce the eventual risk of coronary heart disease as women age. Data are insufficient to assess the benefits and risk of long-term HRT initiated in the perimenopausal years. 15 Data from a large population-based cohort study of older Icelanders were used to analyze the effect of timing of initiation and duration of HRT on CAC.
METHODS
The study population included women aged 67-93 who participated in the Age, Gene/Environment SusceptibilityReykjavik Study (AGES-Reykjavik Study) between 2002 and 2006. This is an ongoing population-based study of Icelandic men and women continuing the Reykjavik Study, an epidemiological study of cardiovascular and other diseases that took place between 1967 and 1997. 16 Information on the design of the AGES-Reykjavik study has been published previously. 17, 18 Data were derived from the AGES-Reykjavik study, the Reykjavik Study midlife examinations, and a national registry that the Icelandic Heart Association maintains. The AGES-Reykjavik examination was completed in three clinic visits, with a participant's full examination finished within a 4-to 6-week window.
Participants completed a detailed questionnaire during the first AGES-Reykjavik clinic visit that included medical history, age at menopause, and detailed questions about use of HRT, including age at initiation, route of administration, and when stopped. Questions were also asked about family history of myocardial infarction, marital status, and physical activity. Past and present physical activity was recorded based on the number of hours of exercise reported per week. 19 Of the 3,287 women in the study, 2,959 had a measurement of CAC at the study site determined using computed tomographic (CT) images acquired using a multidetector CT scanner (Somatom Sensation 4, Siemens Medical Solutions, Erlangen, Germany) using sequential scanning mode and prospective electrocardiographic triggering in a breath hold with 2.5-mm-thick slices, 140 KVp, 50 mAS, and 0.361-second scan time. CAC was quantified using calcium scoring software and results expressed in Agatston scores. 20 There was insufficient questionnaire information in 24 cases, leaving 2,935 women. The sample was further restricted to women who underwent the midlife examination when they were younger than 65, resulting in a final study sample of 2,867 women. This was done to use information from the Reykjavik Study midlife data to create a propensity score for HRT use as observed in late life. This approach gives an opportunity to adjust for and reduce the effect of selection bias. The advantage of using propensity scores is that they allow observational studies to be designed similar to randomized experiments. 21 The covariates from the midlife data selected for use in this analysis were birth year (to account for cohort effect), work status (outside of home or not), raised in the Reykjavik capital area (yes, no), smoking (never, previous, current), education (primary, secondary, college, university), participation in regular physical activity (yes, no), body mass index (BMI), total cholesterol, triglycerides, and systolic blood pressure.
Missing data for late-life variables were imputed using regression methods (regression or multinomial logistic) with age, birth year, and midlife data for same variables as predictors, except for late-life high-sensitivity C-reactive protein (hs-CRP), for which the predictors were late-life BMI, total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, age, and birth year. Late-life BMI was imputed for one woman, pulse pressure for one woman, smoking status for two women, family history of myocardial infarction for three women, late-life education imputed for 17 women (based on midlife education), and hs-CRP for one woman.
Information about history of coronary events was based on a national registry in Iceland for all cases of myocardial infarction and procedures including percutaneous angioplasty and coronary bypass surgery. 17 
Statistical Analysis
All statistical analysis was performed using Stata version 13 (Stata Corp., College Station, TX). Imputations of latelife values were performed using the mi procedure in Stata. A propensity score for ever use of HRT (as measured in late life) was created using the psmatch2 procedure in Stata, with ever use of HRT as a binary response and midlife variables as predictors. 22 In other words, the propensity score was defined as the predicted probability of HRT treatment, e = P(Z = 1|X), from a logistic regression model for HRT use on the midlife variables X. Z = 1 denotes HRT treatment, and Z = 0 denotes absence of treatment. The inverse probability of treatment weight was defined as w = Z/e + (1 À Z)/(1 À e). The propensity score is a balancing score; participants with similar propensity scores will have similar values of the midlife covariates. 22 Balance assessment of the midlife covariates between treatment groups was performed by inspecting standardized differences of variables in the score between treated and untreated women, using the inverse probability of treatment weights, based on the propensity scores, in the pbalchk procedure in Stata. Late-life CAC was then analyzed using inverse probability of treatment weighting (IPTW). First, unadjusted median values of CAC according to age group and HRT use were presented. Then the CAC scores were analyzed using multiple quantile regression to estimate the median CAC score using IPTW. This was done according to duration of HRT use (never, 0-5, 6-15, ≥16 years) and according to initiation of HRT in relation to menopause (never, before menopause, within 1 year after last menses (menopause year), 1-5 years after menopause, >5 years after menopause). Further adjustment to the IPTW analysis of CAC was made by using the late-life variables age at entry into the AGES-Reykjavik Study, age squared, interaction between age and HRT use, BMI, pulse pressure, total cholesterol, LDL-C, hs-CRP, smoking status, education, family history of myocardial infarction, marital status, statin use, and hypertensive medication use. Age-adjusted estimates reflected the cohort's middle age group of 75-79.
The National Bioethics Committee in Iceland and the institutional review board of the Intramural Research Program, National Institute on Aging, National Institutes of Health (Bethesda, MD) approved the study protocol. All participants in the AGES-Reykjavik Study gave informed consent.
RESULTS

Prevalence of HRT Use and Late-Life Characteristics
Of the 2,867 participants, 872 (30.4%) had used HRT, including 312 (10.9%) who were current users; 773 reported having used hormone pills, and 168 had used hormone patches at some time. Older women had a lower prevalence of current HRT use (<70, 19.5%; 70-74, 15.1%; 75-79, 9.0; 80-84, 5.34%; ≥85, 4.3%). Table 1 shows participant characteristics according to history of HRT. Women who had ever used HRT (current and previous) were on average 2.6 years younger than those who had never used HRT (P < .001). After age adjustment, as shown by the adjusted P-values, LDL-C and BMI were significantly lower in those who had ever used HRT, but hs-CRP levels were higher. The rate of history of coronary events was comparable in both groups. Those who had ever used HRT were more likely to be married, use antihypertensive medication, and report family history of myocardial infarction. Participant-reported physical activity was higher in women who had ever used HRT.
Propensity Scores and Inverse Probability of Treatment Weights
All of the midlife covariates were used to create a propensity score for HRT. The covariates associated with HRT use were birth year, systolic blood pressure, cholesterol, BMI, participation in physical activity, and education status. Women with history of HRT use were born later; had lower blood pressure, cholesterol, and BMI; participated in more physical activity; and had a higher education level.
Covariates not associated were working outside of the home, smoking, triglycerides, and being raised in the Reykjavik area. IPTW, based on propensity scores for HRT, successfully balanced the HRT and the non-HRT groups with respect to the midlife covariates. A balance diagnostic graph is shown in Figure 1 . No extremes were found in the estimated weights. Effect sizes are presented as differences in means or medians for continuous variables and odds ratios for binary variables. The current and previous HRT groups were combined and compared with the never HRT group. P-values are expressed with and without adjustment for age using a general linear model for approximately normally distributed variables, quintile regression for C-reactive protein (CRP) and triglycerides, and logistic regression for binary variables. SD = standard deviation; IQR = interquartile range.
CAC Scores According to HRT Use in Different Age Groups
There was a strong, positive, nonlinear (quadratic) association between age and CAC, despite the relatively old age of the study group. The average increase in CAC per year at the median age of 76 was 24 Agatston units (95% confidence interval (CI) = 21-27). Figure 2 shows the steep increase in CAC with age and illustrates the relationship between the groups of never HRT use, previous HRT use, and current HRT use, showing consistently lower CAC scores for current HRT users of all ages. Figure 3 shows a negative linear association between CAC and duration of HRT use, with a difference in median CAC of approximately 50% between the groups of never HRT and 16 or more years of HRT (P < .001).
CAC Scores According to Duration of HRT Treatment
There was a significant negative correlation between total cholesterol and duration of HRT (partial correlation = À0.06, P = .003) and between LDL-C and duration of HRT (partial correlation = À0.07, P < .001) after adjustment for age. hs-CRP level did not correlate with duration of HRT after adjustment for age (P = .08).
CAC and Timing of HRT in Relation to Menopause
Coronary artery calcium score and timing (years from menopause) of initiation of HRT were compared with CAC score in never HRT users (Figure 4) . Women who started HRT in the menopausal year had the lowest CAC scores and significantly lower CAC scores than women who had never used HRT, or 87 Agatston units (95% Figure 4 . Coronary artery calcium (CAC) expressed as Agatston score. CAC score and timing (years from menopause) of initiation of HRT were compared with CAC score in never HRT users. CAC scores were adjusted for late-life variables and inverse probability of treatment weighting for HRT use. CI = 42-132, P ≤ .001). Women who initiated HRT later also had lower CAC scores than never users, or 56 Agatston units (95% CI = 13-98, P = .009).
DISCUSSION
This population-based study of 2,867 older Icelandic women found a strong negative association between duration of HRT use and CAC levels. This association was linear with the duration of HRT. When the duration of HRT use was more than 15 years, median CAC was approximately half that of women who had never used HRT. The lowest CAC levels were observed in those starting HRT at menopause, but even those starting HRT later had lower CAC scores than never users Estrogen and its effect on the cardiovascular system remain controversial. Study results have varied according to hormone preparation, coadministration of progesterone, length of observation or treatment trial, time since menopause, and whether cardiovascular disease was present at onset of HRT. 9, [23] [24] [25] The main criticism of most randomized clinical trials of HRT using clinical cardiovascular endpoints relates to the fact that the women enrolled had an average age of 63-64 and were more than 10 years beyond menopause. 26 Timing and duration of HRT in postmenopausal women are factors affecting cardiovascular outcomes central to the controversy of the "timing hypothesis," which suggests beneficial effects of HRT if initiated early after menopause. 27, 28 Another component of the hypothesis is that the beneficial effects of HRT will be lost if it is initiated several years after menopause. 29 After the early termination of the WHI and its controversy over HRT and cardiovascular health, evidence started to accumulate in support of the hypothesis that the timing of initiation of HRT in relation to menopause onset may affect the association between this therapy and risk of coronary artery disease. 30 Experimental studies in animals have also provided support for this association. 31, 32 Although, the mechanism by which aging and longer periods of estrogen deprivation affect HRT responses is unclear, there are suggestions that estrogen has a moreproinflammatory effect with aging. 33 It is difficult to interpret the current study findings in context of the timing hypothesis, because a surrogate marker of atherosclerosis was used, and event rates were compared using a cross-sectional approach, but the findings suggest that, if HRT is initiated early and continued for longer than 15 years, an association with low CAC will remain. This requires further testing in clinical trials, but research has been lacking in which an upper limit of age or duration of treatment has been assessed in terms of efficacy or safety relating to cardiovascular disease and other outcomes. 27 A randomized controlled trial of more than 1,000 Danish women who had recently entered menopause found that more than 10 years of HRT started early after menopause significantly reduced risk of all-cause mortality, heart failure, and myocardial infarction without an apparent increase in cancer, venous thromboembolism, or stroke. 8 Different dosing regimens and preparations of HRT limit the ability to make comparisons between studies conducted at different times and in geographic regions. Estradiol has been the most common estrogen compound used for HRT in Iceland, and the conjugated equine estrogen used in the WHI has never been available on the market in Iceland.
Sex-specific differences in cardiovascular disease have received attention in recent years. 34 The higher prevalence of myocardial ischemia in women than in men in the presence of normal cardiac catheterization has led to the discussion of microvascular disease being more common in women. 35 The same prevalence of past history of coronary events in HRT users and never-users in the current study is in contrast to several recent clinical trials reporting lower risk of cardiovascular events when HRT is initiated early after menopause. 7, 8 There is no simple explanation for the equal rate of cardiac events. Although lower cholesterol levels in the HRT group may reflect favorable altering of the lipoprotein profile through HRT, they did not seem to affect the principal conclusions of the current study. HRT users were also more likely to be married and have a family history of myocardial infarction. A complex situation of different indications and possible dropout due to mortality or other reasons are among possible explanations for the similar prevalence of cardiovascular events in HRT users and never users. Prospective studies are needed to clarify this issue.
The use of propensity score methodology in analysis of health outcomes data in observational studies has evolved rapidly in recent years. 21 It is evident from Figure 1 that balancing the available midlife covariates using propensity scoring may lead to better matching between the HRT groups for statistical comparisons, although the available information limits the propensity score itself, and there may still be some residual confounding by factors not included in the score.
The main weaknesses of the current findings relate to the cross-sectional nature of the data collection. Also, because the average age in the study was older than 75, it is possible that women at higher risk of cardiovascular disease had dropped out from the cohort because of death or for other reasons. It is also likely that various indications other than menopausal symptoms are behind HRT in the study group, but at the turn of the century, HRT was commonly prescribed to prevent age-associated diseases such as osteoporosis and cardiovascular disease. 37 There is also a possibility of memory bias, particularly in the older participants.
Additional concerns include lack of information whether the estrogen was used with progesterone, dose and estrogen preparation, potential interruptions of therapy, and the wide age range of the cohort. Nevertheless, the large population-based sample of women, the quality of the data, the long observational window of reported HRT use, and the large age range of the cohort provide new information regarding the potential long-term effects of HRT on coronary calcifications. The age span of the study sample exceeds that of previous large epidemiological studies of CAC, but for the overlapping age groups, the CAC values seem comparable with results for women in the Framingham and Multi-Ethnic Study of Atherosclerosis cohorts. 38 The lower CAC in the HRT group in the current study cohort is in line with accumulating evidence from clinical trials and observational studies, indicating that HRT-related cardiovascular outcomes vary according to age and time since menopause. 36 A recent meta-analysis comparing results of observational studies with those of randomized controlled trials indicates that there is little evidence of significant effect estimate differences in health outcomes. 39 This finding also underscores the importance of further research on the long-term role of HRT-related changes in cardiovascular disease risk factors and outcomes. The AGES-Reykjavik study has been ongoing, and further prospective analysis of the association between HRT and cardiovascular outcomes and mortality may provide further information.
In conclusion, the current study results support the hypothesis that HRT initiated early after menopause and taken over the long term may delay or slow the progression of coronary calcification.
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